Abcellera Biologics Inc ABCL

$11.02 -0.01 (-0.09%)

Valuation

Market cap
3,602,597,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
2,588,400
Avg volume
4,314,514
Day's range
$10.95 – $11.55
Shares out
326,618,000
Stochastic %K
10%
Beta
1.59
Analysts
Strong Buy
Price target
$18.58

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

flymetothemoon2 Nov 19, 2:48 AM
$ABCL Could Anthropic's IPO Trigger the Next AI Capital Rotation?
0 replies
flymetothemoon2 Nov 19, 2:40 AM
$ABCL $ABCL just posted a new senior leadership position: Senior Director, Statistical Programming. Why should investors care? This isn’t a discovery or research position. This individual will oversee the transformation of clinical trial data into validated efficacy and safety analyses and submission-ready datasets required for regulatory approval. What’s particularly interesting is that AbCellera is building out an entire internal biometrics division: • VP, Biometrics • Senior Director, Clinical Data Management • Senior Director, Statistical Programming (NEW)
0 replies
flymetothemoon2 Nov 19, 2:39 AM
$ABCL Part 2) Now consider the parallel recruitment efforts across medical affairs, pharmacovigilance, commercial manufacturing, regulatory affairs and drug delivery devices. These are expensive, specialized leadership positions. AbCellera could outsource many of these functions. Instead, it appears to be investing in permanent internal capabilities that can be leveraged across multiple therapeutic programs. Coming just one day after Carl Hansen discussed advancing ABCL635 independently through Phase 3 and potentially commercializing it without a partner, the recruitment strategy deserves particular attention. I believe investors are still underappreciating the magnitude of this transformation. AbCellera isn’t just building the infrastructure to bring one drug to market. It’s building the infrastructure to repeatedly bring drugs to market.
0 replies
desiguy Nov 19, 12:09 AM
$ABCL Great…Stocktradesmoon made a new account as flymetothemoon.. since everyone blocked his old account
0 replies
flymetothemoon2 Nov 18, 8:54 PM 0 replies
flymetothemoon2 Nov 18, 8:35 PM 0 replies
flymetothemoon2 Nov 18, 8:03 PM 0 replies
flymetothemoon2 Nov 18, 8:02 PM 0 replies